Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J 
Welcome,         Profile    Billing    Logout  
 4 Diseases   6 Trials   6 Trials   725 News 


«123456789»
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Clinical, Journal:  Long-term effects of paliperidone palmitate on hospital stay and treatment continuation. (Pubmed Central) -  Mar 22, 2020   
    The introduction of PP1M had a significant impact on long-term clinical outcomes. More than half of patients were still continuing on PP1M at 3 years after initiation and had no admission during 3 years follow-up.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Risperdal Consta (risperidone depot formulation) / J&J
    Trial completion date, Trial primary completion date:  Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS) (clinicaltrials.gov) -  Mar 6, 2020   
    P=N/A,  N=1000, Recruiting, 
    Trial completion date: Mar 2020 --> Oct 2020 Trial completion date: Sep 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Oct 2022
  • ||||||||||  risperidone / Generic mfg., Egis
    [VIRTUAL] FIGHTING NIHILISM: can we do more for our long term chronic patients? (All Screens in Poster Area) -  Feb 20, 2020 - Abstract #EPA2020EPA_2208;    
    Data was collected from 48 patients who have been transition from zuclopenthixol or fluphenazine decanoate (29%) or RLAT (70%) to PP3M... This data suggest that non-acute patients considered stable show clinically relevant improvement in negative symptoms and great improvements in treatment satisfaction when switched from previous RLAT or conventional depot APs to PP3M.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    [VIRTUAL] Patient and caregivers satisfaction associated with monthly or quarterly paliperodone palmitate treatment (All Screens in Poster Area) -  Feb 20, 2020 - Abstract #EPA2020EPA_2159;    
    Most patients on treatment with PP1M or PP3M are involved in making decisions about their treatment, they feel "very satisfied" with their treatment and they perceive their health status as quite good. The main caregivers of patients treated with PP1M or PP3M experience little burden.
  • ||||||||||  risperidone / Generic mfg., Egis, olanzapine / Generic mfg.
    [VIRTUAL] Efficacy of the New Formulations of Atypical Antipsychotics in Patients with Chronic Schizophrenia (All Screens in Poster Area) -  Feb 20, 2020 - Abstract #EPA2020EPA_1429;    
    Pharmacological properties of risperidone microspheres, paliperidone palmitate 1-month and paliperidone palmitate 3-month administered formulations, olanzapine pamoate, aripiprazole monohydrate and aripiprazole lauroxil were analysed and specific properties were underlined... A relatively wide range of long acting injectable atypical antipsychotics is available, therefore choosing between them in clinical practice should be based on a careful analysis of drugs’ specific farmacological properties.
  • ||||||||||  risperidone / Generic mfg., Egis
    [VIRTUAL] Comparative of the effectiveness of long-acting injections of second generation antipsychotic (All Screens in Poster Area) -  Feb 20, 2020 - Abstract #EPA2020EPA_1387;    
    We observed higher percentage of relapse free in patients treated with Paliperidone Palmitate than treated with Risperidone long-acting injection. Patients treated with Paliperidone Palmitate apperars to have greter acceptance and in her family than patients treated with Risperidone long-acting injection.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Clinical, Journal, Real-World Evidence:  Real-world outcomes post-transition to once-every-three-month paliperidone palmitate in patients with schizophrenia within US commercial plans. (Pubmed Central) -  Feb 7, 2020   
    Transitioning to PP3M was associated with an improvement in adherence and in comorbidity-related outcomes related to substance-related and addictive disorders, psychoses, diabetes without chronic complication, and drug abuse. These findings suggest PP3M may enhance comorbidity-related outcomes and adherence while remaining cost neutral.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Comparison of Rehospitalization Rate in Individuals with Schizophrenia Changed from Paliperidone Palmitate to Oral Antipsychotics (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_948;    
    To investigate the efficacy of LAT on the disease course, we compared re-hospitalization rate, drug attitude inventory (DAI), and The Positive and Negative Syndrome Scale (PANSS) in individuals with schizophrenia who had treated with once-monthly paliperidone palmitate and then switched to oral antipsychotics...Immediately after the change of oral medication, dropout occurred in 4 patients, and the duration of LAI in these patients was 2-5 months. The lack of statistical difference between DAI and PANSS after changing to oral drug in LAI can be attributed to the short interval of 6 months.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Efficacy of Paliperidone Palmitate on Psychiatric Symptoms and Attitudes toward Medication in Schizophrenia (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_623;    
    Methods This is a noninterventional, retrospective chart review that explored the changes in medication attitudes toward antipsychotics and clinical outcomes of adults diagnosed with schizophrenia who transitioned from oral antipsychotics to once-monthly paliperidone palmitate (PP1M) in natural clinical settings...Furthermore, the sample size was small, and this study might have had sample selection bias. We hope well-controlled prospective studies will explore the differences between the two groups and confirm favorable findings in all subjects.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Effect of Long-Acting Injections of Paliperidone Palmitate on Clinical and Functional Outcomes in Patients with Schizophrenia Based on Illness Duration (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_274;    
    Methods Patients with schizophrenia who planned to switch their antipsychotic treatment from oral ones to once-monthly Paliperidone LAI were recruited from hospitals in South Korea from 26 July 2010 to 25 July 2017...Discussion Switching to Paliperidone LAI showed significantly better outcomes in schizophrenia patients especially with those with shorter DI. This result suggests that earlier administration of LAI in schizophrenia might lead to better clinical and functional outcomes.
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Comparison between Long-Acting Injectable Aripiprazole versus Paliperidone Palmitate in the Treatment of schizophrenia: Systematic Review and Indirect Treatment Comparison (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_271;    
    Background We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia...However, there was a significant difference in the early dropout rate in terms of lack of efficacy favouring AOM over PP (OR: 0.394; 95% CI: 0.185–0.841). Discussion Within the context of the inherent limitations of the current analysis, our results may suggest that there may be relative advantages for AOM over PP in the short-term treatment of schizophrenia.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  A Novel Polyhalogenated Monoterpene Induces Cell Cycle Arrest and Apoptosis in Breast Cancer Cells. (Pubmed Central) -  Jan 8, 2020   
    In vivo, PPM1 inhibited growth, proliferation, and induced apoptosis in MDA-MB-231 xenografted onto the chick chorioallantoic membrane. Hence, Plocamium polyhalogenated monoterpenes and synthetic analogues deserve further exploration as promising anticancer lead compounds.
  • ||||||||||  vancomycin / Generic mfg.
    Journal:  An operon encoding enzymes for synthesis of a putative extracellular carbohydrate attenuates acquired vancomycin resistance in Streptomyces coelicolor. (Pubmed Central) -  Dec 21, 2019   
    In some suppressor strains the increased resistance was only observed in media with limited phosphate (mimicking the phenotype of wild-type S. coelicolor), but two strains, DT3017_R21 (ppm1vanR) and DT3017_R15 (ppm1 sco2593), retained resistance on media with high phosphate content. These results support the view that vancomycin resistance in S. coelicolor is a trade-off between mechanisms that confer resistance and at least one that interferes with resistance mediated through the sco2594-sco2593-sco2592 operon.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Trial completion, Adherence:  A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness (clinicaltrials.gov) -  Dec 9, 2019   
    P=N/A,  N=30, Completed, 
    Switching to PP1M treatment from oral antipsychotics is likely to be associated with a significant reduction in hospitalization risk along with a delay in time to hospitalization and rehospitalization. Active, not recruiting --> Completed
  • ||||||||||  risperidone / Generic Mfg., Egis, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Clinical, Journal, Real-World Evidence:  Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate. (Pubmed Central) -  Dec 2, 2019   
    Among schizophrenia patients in the US, transitioning to PP1M following oral risperidone/paliperidone treatment was associated with improved comorbidity-related outcomes, higher adherence, and a reduction in HRU, while remaining cost neutral. Furthermore, patients with ≥ 1 all-cause inpatient stay pre-PP1M transition had significantly lower total healthcare costs post-PP1M transition.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  Infection Reveals a Modification of SIRT2 Critical for Chromatin Association. (Pubmed Central) -  Oct 4, 2019   
    Furthermore, we identify a nuclear complex formed by the phosphatases PPM1A and PPM1B, with SIRT2 essential for controlling H3K18 deacetylation and SIRT2-mediated gene repression during infection and necessary for a productive Listeria infection. This study reveals a molecular mechanism regulating SIRT2 function and localization, paving the way for understanding other SIRT2-regulated cellular processes.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Journal, HEOR:  Health Care Resource Utilization and Costs Associated with Transitioning to 3-Month Paliperidone Palmitate Among US Veterans. (Pubmed Central) -  Oct 2, 2019   
    After transitioning to PP3M treatment, veterans had significantly reduced use of oral antipsychotics, HRU, and costs. Although generalizability may be limited due to the veteran population and to those who transitioned according to PP3M prescribing guidelines, future studies in other patient populations may be used to extend these conclusions.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J
    Enrollment open:  A Study of Paliperidone Palmitate 6-Month Formulation (clinicaltrials.gov) -  Sep 27, 2019   
    P3,  N=160, Recruiting, 
    Although generalizability may be limited due to the veteran population and to those who transitioned according to PP3M prescribing guidelines, future studies in other patient populations may be used to extend these conclusions. Not yet recruiting --> Recruiting
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  Streptomyces coelicolor strains lacking polyprenol phosphate mannose synthase and protein O-mannosyl transferase are hyper-susceptible to multiple antibiotics. (Pubmed Central) -  Sep 16, 2019   
    A change in lipid composition was confirmed using Raman spectroscopy, which showed that the ppm1mutant had a greater relative proportion of unsaturated fatty acids compared to the parent or the complemented mutant. Taken together, these data suggest that an inability to synthesize PPM (ppm1) and loss of the glycoproteome (pmtmutant) can detrimentally affect membrane or cell envelope functions leading to loss of intrinsic and, in the case of vancomycin, acquired antibiotic resistance.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  Disruption of the GDP-mannose synthesis pathway in Streptomyces coelicolor results in antibiotic hyper-susceptible phenotypes. (Pubmed Central) -  Sep 16, 2019   
    We showed recently that strains of Streptomyces coelicolor with mutations in the gene ppm1 encoding polyprenol phosphate mannose synthase were both resistant to phage φC31 and have greatly increased susceptibility to antibiotics that mostly act on cell wall biogenesis...Moreover we were unable to generate a strain in which GMP activity encoded by sco3039 and sco4238 is completely knocked out, indicating that GMP is also an important enzyme for growth. Possibly GDP-mannose is at a metabolic branch point that supplies alternative nucleotide sugar donors.
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Saphris (asenapine) / Allergan, Lundbeck, Meiji Seika, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal, HEOR:  Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA. (Pubmed Central) -  Sep 11, 2019   
    Possibly GDP-mannose is at a metabolic branch point that supplies alternative nucleotide sugar donors. As market shares of atypical antipsychotics are predicted to increase, payers may wish to re-evaluate their use.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J
    New P3 trial:  A Study of Paliperidone Palmitate 6-Month Formulation (clinicaltrials.gov) -  Aug 28, 2019   
    P3,  N=160, Not yet recruiting,